The time to diagnosis (TtD) of Ewing tumors is one of the longest among pediatric tumors. Its precise consequences, however, have not been studied well. We analyzed the distribution of TtD for Ewing tumors in children and adolescents and its association with clinical features, tumor characteristics, surgical outcome, and long-term survival.
INTRODUCTION
Ewing tumors are the second most frequent bone tumors in children and adolescents.
1,2 Despite progress in treatment, the prognosis remains poor for large and unresectable or metastatic tumors. 3, 4 The time to diagnosis (TtD) for Ewing tumors is one of the longest among pediatric tumors, with reported medians from 3 to 6 months. [5] [6] [7] [8] [9] [10] [11] Delayed diagnosis causes remorse for physicians and parents 12 and is a leading cause of malpractice claims. 5 Nevertheless, Bacci et al 13, 14 found a paradoxical inverse relationship between TtD and the presence of metastases, and three other studies did not find a statistically significant relationship between TtD and survival. 7, 9, 11 The paradoxical relationship between long TtD and less frequent metastases, as found by Bacci et al, 13, 14 is probably as a result of residual confounding with the type of tumor progression, because there is no possible causal link between long TtD and better outcome: delaying the diagnosis cannot in itself improve the outcome. Rapidly growing and metastatic tumors might produce swift and intense clinical signs, thus leading to rapid consultation and diagnosis, but only for very advanced tumors. Conversely, slow-growing tumors might cause mild and progressive clinical signs that would lead to a long period of development before diagnosis. These studies were limited by the small number of patients (n Ͻ 50), 7, 11, 15, 16 that they were singlecenter 7, 13, 14 or retrospective, 7, 9, 11, 15, 16 that they pooled analyses for pediatric and adult patients 9, 11, [13] [14] [15] [16] or for several types of bone tumors, 7 ,15 that they were restricted to a specific site (pelvic 11 or rib 16 tumors), and/or that they lacked multivariable analyses despite the presence of potential confounders. 7, 9, 11, [14] [15] [16] Thus, their findings must be confirmed. Moreover, we lack data on the relationship between TtD and other prognostic factors, such as site of metastasis, tumor volume, histologic response to chemotherapy, or surgical outcome. Therefore, our goal was to study the TtD of Ewing tumors in children and adolescents in terms of distribution, potential determinants, and association with clinical features, tumor characteristics, surgical outcome, and survival. We used large, national, and prospectively collected databases and took into account potential confounding factors.
PATIENTS AND METHODS

Study Design
We performed an ancillary study of pooled data from two prospective multicenter clinical trials by the Société Française des Cancers de l'Enfant, EW 88 3 and EW 93. 17 These studies aimed to determine whether a riskfactor-adapted chemotherapy treatment would improve the outcome. Patients received the same induction chemotherapy, then a second chemotherapy depending on their response to the first, then a local therapy (surgical resection and/or radiotherapy), and finally a consolidation chemotherapy according to risk groups. 3, 17 This secondary analysis is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.
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Inclusion Criteria
Patients throughout France were included between 1988 and 2000. 3, 17 Eligible patients had primary bone tumors diagnosed as Ewing tumors or peripheral neuroectodermal bone tumors. Their diagnoses were based on histologic analyses of biopsies and a panel of reference pathologists reviewed the material to confirm the diagnoses. 3, 17 No upper age limit prohibited participation in the main studies, but the secondary analyses were limited to patients younger than 21 years old.
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Data Collection
The following data were prospectively recorded at the time of diagnosis: age, sex, region of residence, symptoms and clinical signs (palpable mass, pain, fever higher than 38°C during 5 days without any identified cause, peripheral nerve compression, spinal-cord or cauda equina compression), date of onset of symptoms, date of diagnosis (ie, date of biopsy or surgery in case of initial resection), date of onset of treatment (first day of chemotherapy), tumor site, tumor volume, presence of metastases and site (lung, bones, medulla), surgical outcome (whether surgical treatment was received or not, mutilating surgery [amputation or disarticulation], completeness of resection), histologic response to chemotherapy (percentage of residual cells after chemotherapy on the surgical specimen, based on a grading system from Huvos et al [20] [21] [22] ), and overall survival. Pretreatment staging procedures were as described previously 3, 17 : computed tomography scans, whole-body technetium bone scan, multiple bone-marrow aspirates, and biopsies. The TtD, expressed in days, was defined as the time from onset of symptoms to the date of diagnosis. The pretreatment interval was defined as the interval between symptom onset and the first day of chemotherapy.
Statistical Analysis
First, we described the demographic, clinical, and tumor characteristics and the distribution of TtD. Second, we studied the association of patient and tumor characteristics and TtD on univariable and multivariable analyses (logistic regression or multiple linear models). Third, we studied the associations of cofactors of interest, TtD, and survival; first, for the entire population (Kaplan-Meier survival analysis and log-rank test), then, after stratification for the identified prognostic factors or after adjustments for the cofactors of interest in Cox models (after verification of the hypothesis of the proportionality of risks). Potential predictors were included if relevant, according to the literature or to oncologist experts. The multivariable analysis of the association of TtD and outcome was also adjusted for the trial arms. TtD was considered successively as a predicted variable (to search for potential determinants of long TtD) and then as a predictor (to study the possible effect of TtD on tumor and clinical outcome). TtD was considered a continuous variable (including Kruskal-Wallis test when the distribution of TtD was compared between several groups) or after transformation with fractional polynomials (in case of deviance from linearity) of the smallest degree and with the maximum likelihood, according to the Royston et al 23 model-selection algorithm. Results for the association of TtD were also shown, for more readability, with TtD as a binary variable after dichotomization around the median. Similarly, other variables were handled continuously and as binary or categoric variables after dichotomization around the median (12 years for age) or usual thresholds (12 years for age, 7,13 100/200 mL for tumor volume, 3, 17 or 0/10/30% for histologic response to chemotherapy 3, 17 ). For the analysis of the distribution of the TtD among regions of France, we grouped the treating centers into the eight demographic areas of France.
24 Data analyses involved use of R 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria) and STATA 9.2 (StataCorp).
The sample size of the study was a priori fixed given its design (ancillary analysis of pooled data from two prospective multicenter clinical trials). A posteriori calculations indicated that the sample size offered 80% statistical power (alpha risk, 5%) to detect a difference in TtD of at least 43 days between patients with or without metastasis and to detect a difference in 10-year survival of at least 13% between patients with TtD that was shorter or longer than the median.
Ethics Statement
Protocols EW 88 3 and EW 93 17 were approved by the institutional review boards of all participating centers, which included the authorization for secondary analysis. Written informed consent was obtained from the patients and/or their guardians.
RESULTS
Population and Distribution of Time to Diagnosis
Among the 455 patients younger than 21 years included in the EW88 and EW93 studies who received treatment in France, TtD could be determined for 436 patients (96%). Median age at diagnosis was 12 years (interquartile range [IQR], 9 to 15 years). Patient and tumor characteristics are listed in Table 1 and Table 2 . The median follow-up period was 8.4 years (IQR, 7 to 11 years). The 5-and 10-year survival rates were 59% (95% CI, 55% to 64%) and 54% (95% CI, 49% to 59%), respectively.
The median TtD for the 436 patients was 70 days (IQR, 27 to 146 days; range, 1 to 1,461 days); 72% of patients received a diagnosis after 30 days (1 month) and 19% received a diagnosis after 182 days (6 months) after symptom onset. Length of TtD did not vary by treating center or among the eight demographic areas of France (P Ͼ .2) and did not decrease over time during the study period (P Ͼ .2; Appendix Fig A1 [online only] ). The median pretreatment interval was 83 days (IQR, 38 to 157 days).
Relationship of TtD, Clinical Features, and Tumor Site
On univariable analysis, factors significantly associated with increased TtD were older age (Fig 1) , presence of pain at the time of diagnosis, and site of the tumor. But increased TtD was not associated with sex, presence of a palpable mass at the time of diagnosis, presence of fever, or presence of a peripheral nerve compression or spinal-cord or cauda equina compression (Table 1) . After adjustment, two factors remained significantly and independently associated with long TtD (as a continuous or binary variable): older age at diagnosis and tumor site. Tumor sites that increased TtD (listed by increasing length of TtD) were skull, ribs or vertebrae, limbs, pelvis, and hand or foot ( Table 1) .
Relationships of TtD, Tumor Features, and Outcome
TtD was significantly associated with tumor volume (as a continuous and binary variable) on univariable analysis but not after adjustment for age and tumor site ( Table 2 ). The presence of pain at diagnosis was significantly associated with tumor volume (median, 139 mL with pain v 71 mL without pain; P ϭ 10
Ϫ4
). TtD did not significantly (P Ͼ .1) differ by presence of metastases, site of metastases (lung, bones, medulla), or whether the patient received surgical treatment (Table 2) . TtD did not significantly differ by nonmutilating resection or mutilating or no surgery (median, 62 v 81 days; P ϭ .07; analyses limited to patients with tumor of the limbs and hand or foot yielded similar results). Among the 274 patients who underwent surgery, TtD did not significantly differ by macroscopic completeness of the resection (median, 60 days if complete v 93 if not; P Ͼ .2) or between resection margins (Table 2) .
Among the 253 patients who underwent surgery and had a histologic analysis of viable cells, the response to chemotherapy was better for patients with a short TtD. The median TtD for patients with less than 10% versus Ն 10% viable cells was 55 versus 82 days, respectively (P ϭ .03; Table 2 ). The difference was no more statistically significant with histologic grading analyzed as a continuous variable (linear regression, P ϭ .24; no deviance to linearity) in four classes (median TtD: 0% viable cells, 54 days; 1% to 9% viable cells, 60 days; 10% to 29% viable cells, 81 days; Ն 30% viable cells, 82 days; P ϭ .11) or by complete necrosis or not (54 days for 0% viable cells v 69 days for Ն 1% viable cells; P ϭ .08). After adjustment for age, tumor site, and volume, the histologic response to chemotherapy was not significantly associated with TtD as a continuous variable (P ϭ .60) or a binary variable (adjusted odds ratio, 1.3; 95% CI, 0.75 to 2.4; P ϭ .33); only volume remained significantly associated with histologic response.
Survival was not significantly associated with TtD as a continuous variable (or after transformation with fractional polynomials), divided into five sections (Appendix Fig A2, online only) , dichotomized at its median (P ϭ .17; Fig 2) , or at its 75th percentile. After adjustments in Cox models for all covariables of interest (age, tumor site, metastasis, tumor volume, surgery, resection margins, histologic response to chemotherapy, and trial arms), TtD 
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was not significantly associated with survival (P Ͼ .2). Analysis of the relationship between pretreatment interval and outcome yielded similar results.
DISCUSSION
Our results are based on a large, multicenter population that allowed us to avoid the recruitment bias of single-center studies. We estimated the incidence of Ewing tumors in France during the study period using data from the national cancer registry 1 and found that our study covered approximately 83% of these cases and thus could practically be considered a national population-based incidence. We used multivariable analysis to account for confounding factors and treated TtD as a continuous variable, using fractional polynomials. Our data were prospectively collected, and TtD data were missing for only 4% of the patients. Disease extension was determined in all patients and was based on standardized methods. Survival analyses benefitted from a long follow-up period. Even if a larger sample size might detect a statistically significant decrease in survival, the existence of a truly clinically significant difference is unlikely.
The TtD of Ewing tumors in children and adolescents was long, without improvement during the study period. Older age and tumor site (specifically, pelvis or hand and foot) were the main independent factors associated with long TtD. The association between older age and long TtD, already noted with other pediatric cancers, 5, 25, 26 could be because of the tumor, because the type of tumor progression could depend on age. Ewing tumors in young §The associations remained significant with tumor volume as a continuous variable. ¶Analyses for each site of metastasis (lung, bones, medulla) did not reveal any significant association with TtD (P Ͼ .1).
children may grow more rapidly and produce more intense clinical signs than in older children, thus leading to more rapid consultation and diagnosis. Also, young children are watched more closely by their parents and monitored more closely by their physicians than are older children; conversely, some older children or adolescents may be reluctant to disclose symptoms or take care of themselves, 25 as was described in other fields of adolescent medicine and the health care system. 27 Similarly, the association between tumor site and TtD could be because of the type of symptoms and interpretation, depending on the anatomic site of the tumor. For example, an iliac tumor with intra-abdominal development could grow more discreetly than a tumor on the face, and vague and intermittent abdominal pain are less specific symptoms than a palpable mass on the face. This also could be owing to the type of biologic tumor progression itself, which could depend on the site.
It might seem surprising that the presence of pain was associated with longer rather than shorter TtD. Indeed, the presence of pain might encourage the patient to consult early and the clinician to prescribe imaging, thus shortening both patient and physician delays. In our study, the presence of pain was considered at the time of diagnosis, not as the first symptom. Pain was significantly associated with tumor volume, which was significantly associated with TtD. Thus, pain should probably be interpreted as a consequence of the length of the TtD.
Some initial severity factors were associated with long TtD, such as increased tumor volume and decreased histologic response to chemotherapy, but not peripheral nerve, spinal-cord or cauda equina compression, presence or site of metastasis, presence or type of surgical treatment, completeness of the resection, or survival. Moreover, the association of histologic response to chemotherapy and TtD did not persist after adjustment for tumor volume, so tumor volume may be an intermediary factor; long TtD leads to a large tumor, which increases the risk of poor histologic response to chemotherapy. Finally, we did not show a significant relationship between long TtD and unfavorable outcome, particularly survival. TtD may not be associated with disease severity, the association may have been erased by the treatment, or the association may be masked by residual confounding owing to incomplete adjustment, particularly for the tumor biology, which could be linked to both TtD and prognosis. The association of longer TtD with older age, larger tumor size, and tumors located at the extremities was previously observed in a series of 575 patients younger than 21 years with soft-tissue sarcomas, including 31 extraosseous Ewing-family tumors. 26 In that study, longer TtD was associated with decreased survival. This possible consequence of long TtD for soft tissue sarcoma may not be applicable to Ewing bone sarcomas, as was shown by another study in the same center, 13, 14 which was confirmed by our current study.
The study limitations include imprecise measurement of TtD; because the onset of symptoms may be vague for some patients, it may have produced a nondifferential classification bias. Our database was from two clinical trials, which could lead to a selection bias. Nevertheless, the inclusion criteria were not restrictive, so we estimate that most of the young patients with Ewing tumors in France during the study period were included (83%). The trials are quite mature, but no major changes in health care delivery in France have occurred recently. Therefore, the length of TtD for Ewing tumors is probably the same at present. In a recent literature review of 98 studies of TtD for cancers in children older than 40 years, TtD did not significantly decrease for any tumor. 5 Our study was not able to evaluate the psychological consequences of delayed diagnosis for children, adolescents, parents, and primary care physicians, nor legal consequences such as lawsuits. Two studies undertook semistructured interviews with parents whose children had a diagnosis of cancer and found that their experiences during the TtD had longstanding adverse effects on their reaction to the diagnosis of cancer, subsequent adjustment, and confidence in the health care system. 12, 28 In a review of 59 instances of lawsuits alleging delayed diagnosis of pediatric cancer in Canada and France, Ewing tumors accounted for five cases (8%). Court-appointed experts concluded that delayed diagnosis had no consequences on metastases or survival (three cases) or had any consequences on tumor size, surgery and sequelae (one case), or metastasis and survival (one case). 5 The conclusions about the individual consequences of a given delay in diagnosis might differ from those drawn from the analysis of a cohort of patients.
TtD of Ewing tumors is still long, especially for adolescents and for certain tumor sites. We did not observe any significant Overall survival by time to diagnosis (10-year survival, 56% v 50%; relative risk, 1.22; 95% CI, 0.92 to 1.61; P ϭ .17). Analysis yielded similar results (P Ͼ .2) with time to diagnosis as a continuous variable, after transformation with fractional polynomials, or after multivariable analysis (after adjustments for age, tumor site, metastasis, tumor volume, surgery, resection margins, histologic response to chemotherapy, and trial arms).
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www.jco.org decrease in TtD over time, despite the increased availability of modern imaging methods, probably because the diagnosis of bone tumors in children still relies mainly on clinical skills. Therefore, progress is necessary to reduce diagnostic delays by educating parents and primary care physicians, as is the case with other types of pediatric tumors. 29 Distinguishing bone tumors from other less serious conditions and rapid referral to a treating pediatric oncology center is needed to alleviate the psychological consequences of delayed diagnosis and treatment. Nevertheless, our study and other literature did not reveal any association of TtD and metastases, surgical outcome, or survival. These findings should be used to inform parents at diagnosis, they may be comforting for both parents and treating physicians by toning down the perception of the supposed consequences of long TtD, and they may have legal implications for expert testimony in lawsuits.
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